# Peppermint Venture Partners

> Peppermint Venture Partners is a VC fund backing Health Care. See 12 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Berlin, Germany
- Total investments: 12
- Last investment: Apr 2024
- Lead investor: 33%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/2110009/
- X (Twitter): https://twitter.com/peppermint_vp
- Website: https://www.pvp.health/

Peppermint Venture Partners is a VC fund in Berlin focused on Health Care and Biotechnology. PVP is a private venture capital firm based in Berlin, investing in early-stage healthcare companies across Europe with a focus on medical device, digital health, and platform technology companies. Peppermint VenturePartners was established in 2008 by Ingeborg Neumann, Dr. Joachim Rautter and Dr. Klaus Stöckemann.

## Contacts

5 contacts available for Peppermint Venture Partners. Shizune tracks 2 team members at Peppermint Venture Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/peppermint-venture-partners?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $1.8M–$3.8M |
| Series B | $3.3M–$11M |
| Series C | $6.9M–$7.7M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 4 | 33% |
| Biotechnology | 4 | 33% |
| Medical | 3 | 25% |
| Medical Device | 3 | 25% |
| Software | 1 | 8% |

16 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 3 | 25% |
| Series A | 2 | 17% |
| Series C | 2 | 17% |
| Series D | 1 | 8% |
| Funding Round | 1 | 8% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Germany | 5 | 42% |
| Belgium | 1 | 8% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Joachim Rautter | Co-Founder and Managing Director | 5 | https://shizune.co/investors/profile/joachim-rautter-c050 |
| Klaus Stoeckemann | Managing Director & Co-Founder | 2 | https://shizune.co/investors/profile/klaus-stoeckemann |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| CryoTherapeutics | CryoTherapeutics is focusing on the development, demonstration of clinical benefit, and early-stage commercialization of a proprietary cryotherapy system for use in the treatment of coronary artery disease that causes heart attacks. The safety and efficacy of cryoenergy in the cardiovascular system has been demonstrated and CryoTherapeutics intendsto extend the benefits of cryoenergy to the problem of diseased coronary arteries. | $10.8M | Series B | Apr 02, 2024 |  |
| Labforward | Labforward supports laboratory teams on their quest for groundbreaking discoveries and delivering innovative high-quality products. With digital tools for laboratories, it increases productivity and improves efficiency in laboratories. The company's products include the user-friendly electronic laboratory notebook (ELN) Labfolder and theInternet-of-Things (IoT) platform Laboperator. The digital connectivity of laboratories and innovative data management is a focus topic in industry and research. In a fragmented landscape of high-tech equipment and specialized software, Labforward links data silos and helps to eliminate costly and error-prone data transfers. Based on this horizontal connectivity, the software Laboperator enables the remote control and monitoring of laboratory equipment, the integration of LIMS systems, databases and special software as well as the automation of workflows. The Labfolder data platform aggregates both automatically recorded and manually added data and enables the review, sharing, retrieval and validation of data by means of a collaborative ELN. Whether life sciences, chemical synthesis, analytics, quality control or research and development: no matter how specific the field or task of a laboratory may be, the way it works and the requirements for data management have a common core. Labforward focuses on this core. | $6.1M | Series B | Jan 08, 2021 |  |
| CryoTherapeutics | CryoTherapeutics is focusing on the development, demonstration of clinical benefit, and early-stage commercialization of a proprietary cryotherapy system for use in the treatment of coronary artery disease that causes heart attacks. The safety and efficacy of cryoenergy in the cardiovascular system has been demonstrated and CryoTherapeutics intendsto extend the benefits of cryoenergy to the problem of diseased coronary arteries. | $7.7M | Series B | Jun 27, 2019 |  |
| Miracor Medical | Miracor Medical operates as a medical device company. It develops and commercializes a pressure-controlled intermittent coronary sinus occlusion (PiCSO) impulse system for cardiac surgeons to facilitate the PiCSO treatment for myocardial infarction/heart attack patients undergoing coronary artery bypass grafting surgery. Miracor Medicaloffers a therapy for improving micro-vascular perfusion functions through the coronary sinus. Werner Mohl founded it in 2008, with its headquarters in Awans in Belgium. | $27.4M | Series D | Jan 04, 2018 |  |
| Miracor Medical | Miracor Medical operates as a medical device company. It develops and commercializes a pressure-controlled intermittent coronary sinus occlusion (PiCSO) impulse system for cardiac surgeons to facilitate the PiCSO treatment for myocardial infarction/heart attack patients undergoing coronary artery bypass grafting surgery. Miracor Medicaloffers a therapy for improving micro-vascular perfusion functions through the coronary sinus. Werner Mohl founded it in 2008, with its headquarters in Awans in Belgium. | $7.7M | Series C | Oct 25, 2016 |  |
| CryoTherapeutics | CryoTherapeutics is focusing on the development, demonstration of clinical benefit, and early-stage commercialization of a proprietary cryotherapy system for use in the treatment of coronary artery disease that causes heart attacks. The safety and efficacy of cryoenergy in the cardiovascular system has been demonstrated and CryoTherapeutics intendsto extend the benefits of cryoenergy to the problem of diseased coronary arteries. | $5.7M | Series B | Jul 07, 2016 |  |
| CEVEC Pharmaceuticals | CEVEC is a center of expertise for the production of biopharmaceuticals using a unique human cell-based expression system.CAP-Go enables the production of proteins “beyond antibodies”. Complex, glycosylated proteins represent a significant portion of the human proteome and are notoriously difficult to express in conventional cell lines such asCHO. The CAP-Go expression platform comprises a portfolio of glyco-optimized human suspension cell lines for the highly efficient production of a broad range of difficult to express recombinant proteins with authentic human post-translational modifications or on demand tailor-made glycosylation patterns. | $4.9M |  | Jul 30, 2015 |  |
| Humedics | Humedics, based in Berlin, focuses on rapid and precise liver function measurement using LiMAx, its innovative breath analysis technology. This easy-to-use bedside test provides doctors with accurate information to support decision making in tailoring the medical treatment to the individual level of each patient and to improve patient outcomes.LiMAx has already been used on thousands of patients and the company is currently expanding its operation globally. | $6.9M | Series C | Nov 10, 2014 |  |
| Implandata Ophthalmic Products | Implandata Ophthalmic Products is an early stage, privately-held, venture capital funded medical device company based in Hannover, Germany. Implandata Ophthalmic Products is a medical device company offering a new technology for the treatment and management of glaucoma patients. It identifies an underserved area in care of glaucoma patients,creating disruptive solutions for better and more efficient glaucoma therapy, to the benefit of glaucoma patients, families, and care givers by integrating innovative medical technology with information technology.IOP has developed a novel technology for 24 hour measurement of intraocular pressure, by which monitoring and therapy of glaucoma patients will be improved. This solution will allow a more efficient treatment and management of glaucoma patients.Implandata Ophthalmic Products was founded on 2010. | $3.3M | Series B | Oct 27, 2014 |  |
| CryoTherapeutics | CryoTherapeutics is focusing on the development, demonstration of clinical benefit, and early-stage commercialization of a proprietary cryotherapy system for use in the treatment of coronary artery disease that causes heart attacks. The safety and efficacy of cryoenergy in the cardiovascular system has been demonstrated and CryoTherapeutics intendsto extend the benefits of cryoenergy to the problem of diseased coronary arteries. | $3.8M | Series A | May 06, 2014 |  |

10 of 12 investments shown.

## Co-investors
- [NRW.BANK](https://shizune.co/investors/profile/nrw-bank) — VC Fund, 4 deals together
- [BioMedPartners](https://shizune.co/investors/profile/biomedpartners) — VC Fund, 3 deals together
- [Creathor Ventures](https://shizune.co/investors/profile/creathor-venture-management) — VC Fund, 3 deals together
- [KfW](https://shizune.co/investors/profile/kfw) — VC Fund, 3 deals together
- [Meusinvest (Noshaq)](https://shizune.co/investors/profile/meusinvest) — VC Fund, 3 deals together
- [Delta Partners](https://shizune.co/investors/profile/delta-partners) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund
- [HV Capital](https://shizune.co/investors/profile/holtzbrinck-ventures) — VC Fund
- [IBB Ventures](https://shizune.co/investors/profile/ibb) — VC Fund

## Featured in investor lists
- [Medical Investors in Germany](https://shizune.co/investors/medical-investors-germany)
- [Biotech Investors in Germany](https://shizune.co/investors/biotech-investors-germany)
- [Biotech VC Funds in Germany](https://shizune.co/investors/biotech-vc-funds-germany)
- [Biotechnology VC Funds in Germany](https://shizune.co/investors/biotechnology-vc-funds-germany)

## FAQ

### What does Peppermint Venture Partners invest in?

Peppermint Venture Partners invests primarily in Health Care, Biotechnology and Medical startups, most often at Series B and Series A stage. Most of the 12 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Peppermint Venture Partners's check size?

Peppermint Venture Partners typically joins rounds of $1.8M–$3.8M at Series A, $3.3M–$11M at Series B and $6.9M–$7.7M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Peppermint Venture Partners participates in.

### How do I contact Peppermint Venture Partners?

Public channels for Peppermint Venture Partners include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Peppermint Venture Partners?

The team at Peppermint Venture Partners includes Joachim Rautter (Co-Founder and Managing Director) and Klaus Stoeckemann (Managing Director & Co-Founder). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co